Matching articles for "ondansetron"
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • February 22, 2021; (Issue 1618)
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • February 22, 2021; (Issue 1618)
...
View the Comparison Table: Drugs for Parkinson's Disease
Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis
The Medical Letter on Drugs and Therapeutics • January 11, 2021; (Issue 1615)
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic...
The FDA has approved Gimoti (Evoke), a nasal
spray formulation of the dopamine-2 (D2) receptor
antagonist metoclopramide, for relief of symptoms in
adults with acute and recurrent diabetic gastroparesis.
Metoclopramide (Reglan, and generics) has been
available for years in conventional and orally-disintegrating
tablets and in an injectable formulation.
It is the only drug that is FDA-approved for treatment
of diabetic gastroparesis.
IV Amisulpride (Barhemsys) for Postoperative Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • December 28, 2020; (Issue 1614)
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It...
The FDA has approved IV amisulpride (Barhemsys –
Acacia), a selective dopamine-2 and -3 (D2/D3) receptor
antagonist, for prevention and treatment of postoperative
nausea and vomiting (PONV) in adults. It is the first
antiemetic to be approved for rescue treatment of
PONV in patients who have symptoms despite receiving
antiemetic prophylaxis. Oral formulations of amisulpride
are available in Europe for treatment of schizophrenia
and acute psychotic episodes.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • March 23, 2020; (Issue 1594)
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant...
Irritable bowel syndrome (IBS) is a common disorder
characterized by recurrent abdominal pain and altered
bowel habits, often accompanied by bloating.IBS
is classified according to the predominant bowel
symptom as IBS with constipation (IBS-C), IBS with
diarrhea (IBS-D), mixed type (IBS-M), or unclassified
(IBS-U). Alterations in the microbiome, stress
responses, sensory and motor function of the gut,
and host genetic factors may be contributing factors.
Since the exact cause of IBS is unknown, the goal of
treatment is symptom control.
Table: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
The Medical Letter on Drugs and Therapeutics • March 23, 2020; (Issue 1594)
...
View the Table: Safety of Drugs for IBS in Pregnancy and Lactation
Obalon Balloon System - Another Gastric Balloon for Weight Loss
The Medical Letter on Drugs and Therapeutics • June 19, 2017; (Issue 1523)
The FDA has approved the Obalon Balloon System
(Obalon), a swallowable intragastric gas-filled balloon
device, to facilitate weight loss in adults with a body
mass index (BMI) of 30-40 kg/m2 who have not...
The FDA has approved the Obalon Balloon System
(Obalon), a swallowable intragastric gas-filled balloon
device, to facilitate weight loss in adults with a body
mass index (BMI) of 30-40 kg/m2 who have not been
able to lose weight through diet and exercise. Two
other gastric balloon devices, ReShape and Orbera,
were approved earlier.
Drugs for Irritable Bowel Syndrome
The Medical Letter on Drugs and Therapeutics • September 26, 2016; (Issue 1504)
Irritable bowel syndrome (IBS) is a common disorder
characterized by chronic, intermittent abdominal pain
or discomfort and altered bowel habits. It is subtyped
according to the predominant bowel symptom as...
Irritable bowel syndrome (IBS) is a common disorder
characterized by chronic, intermittent abdominal pain
or discomfort and altered bowel habits. It is subtyped
according to the predominant bowel symptom as IBS
with constipation (IBS-C), IBS with diarrhea (IBS-D),
mixed type (IBS-M), or unclassified (IBS-U). Since the
exact cause of IBS is unknown, the goal of treatment
is symptom control.
Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • February 1, 2016; (Issue 1487)
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with...
The FDA has approved rolapitant (Varubi – Tesaro),
an oral substance P/neurokinin 1 (NK1) receptor
antagonist, for use with other antiemetics to prevent
delayed nausea and vomiting associated with cancer
chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) and netupitant (only available
in combination with the 5-HT3 receptor antagonist
palonosetron as Akynzeo) were approved earlier for
prevention of both acute and delayed chemotherapy-induced
nausea and vomiting.
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • April 27, 2015; (Issue 1467)
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist palonosetron,
for prevention of acute and delayed nausea and
vomiting associated with cancer chemotherapy
in adults. Akynzeo is the first product to combine
drugs from these two classes. Palonosetron (Aloxi)
is also available as a single agent for prevention of
chemotherapy-induced and postoperative nausea
and vomiting. Netupitant is the second substance
P/NK1 receptor antagonist to be approved in the US;
aprepitant (Emend) was the first.
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2013; (Issue 135)
The motor symptoms of Parkinson's disease (PD) are
caused primarily by progressive degeneration of
dopaminergic neurons in the substantia nigra. The non-motor
symptoms of the disease are thought to be...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by progressive degeneration of
dopaminergic neurons in the substantia nigra. The non-motor
symptoms of the disease are thought to be caused
by degeneration of other neurotransmitter systems.
In Brief: Intravenous Ondansetron (Zofran) 32 mg Withdrawn
The Medical Letter on Drugs and Therapeutics • December 24, 2012; (Issue 1406)
The FDA has announced that the single 32-mg IV dose of ondansetron (Zofran, and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it...
The FDA has announced that the single 32-mg IV dose of ondansetron (Zofran, and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it can prolong the QT interval and could possibly cause a torsades de pointes cardiac arrhythmia. For this indication, the only recommended dose of IV ondansetron is 0.15 mg/kg (maximum 16 mg/dose) every 4 hours for 3 doses. There are no changes in the recommended dosing regimens for oral ondansetron or for IV ondansetron used for prevention of postoperative nausea and vomiting.
Download complete U.S. English article
Download complete U.S. English article
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • January 1, 2011; (Issue 101)
Parkinson’s disease (PD) is caused primarily by progressive
degeneration of dopamine-containing neurons
in the substantia nigra. Dopamine itself cannot be
used to treat PD because it does not cross the...
Parkinson’s disease (PD) is caused primarily by progressive
degeneration of dopamine-containing neurons
in the substantia nigra. Dopamine itself cannot be
used to treat PD because it does not cross the blood-brain
barrier.
Medical Marijuana
The Medical Letter on Drugs and Therapeutics • January 25, 2010; (Issue 1330)
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some...
Fourteen states in the US - Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington - now permit, or soon will permit, some medical use of marijuana (Cannabis sativa). In some states, licensed facilities dispense botanical cannabis by prescription. In others, limited self-cultivation is permitted for medical use.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Click here to view the free full article.
Click here to view the free full article.
A Granisetron Patch (Sancuso)
The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor...
The treatment of choice to prevent emesis due to highand moderate-risk emetogenic drugs used in cancer chemotherapy is aprepitant plus a serotonin receptor antagonist plus dexamethasone. Four serotonin receptor antagonists are available in the US in intravenous (IV) formulations for prevention of nausea and vomiting due to cancer chemotherapy, and 3 of these are also available for oral use. Now the FDA has approved one of these, granisetron, in a transdermal formulation (Sancuso - ProStrakan).
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • October 1, 2007; (Issue 62)
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the...
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Apomorphine (Apokyn) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • January 17, 2005; (Issue 1200)
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with...
Apomorphine (Apokyn - Mylan/Bertek), an injected non-ergot dopamine agonist, was recently approved by the FDA for intermittent subcutaneous (SC) treatment of hypomobility ("off" episodes) in patients with advanced Parkinson's disease. It has been available in Europe for many years.
Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • March 29, 2004; (Issue 1179)
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and dexamethasone to prevent both acute and delayed nausea and vomiting due to highly emetogenic drugs (Medical Letter 2003; 45:62).
Aprepitant (Emend) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • August 4, 2003; (Issue 1162)
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor...
Aprepitant (Emend - Merck), the first substance P/neurokinin 1 (NK1) receptor antagonist to be approved by the FDA, is now available for oral use with corticosteroids and selective serotonin (5-HT3) receptor antagonists to prevent nausea and vomiting caused by highly emetogenic anticancer drugs such as cisplatin.
Drug Interactions
The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Drugs That May Cause Psychiatric Symptoms
The Medical Letter on Drugs and Therapeutics • July 8, 2002; (Issue 1134)
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously...
Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.
Dolasetron for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • May 8, 1998; (Issue 1026)
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both...
Dolasetron (Anzemet - Hoechst Marion Roussel), a selective serotonin (5-HT3) receptor antagonist similar to ondansetron (Zofran) and granisetron (Kytril - Medical Letter, 36:61, 1994) is now available for both oral and intravenous use in prevention of nausea and vomiting due to cancer chemotherapy. A 5-HT3 antagonist plus dexamethasone (Decadron, and others) is the most effective regimen for prevention of acute vomiting caused by cancer chemotherapy. Dolasetron has also been approved by the FDA for prevention and treatment of postoperative nausea and vomiting.
Granisetron to Prevent Vomiting After Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • July 8, 1994; (Issue 926)
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although...
Granisetron, a serotonin (5-HT) antagonist similar to ondansetron, was recently approved by the US Food and Drug Administration for prevention of nausea and vomiting due to cancer chemotherapy. Although available in an oral formulation in other countries, granisetron is available here only for intravenous (IV) use.
Drugs for Vomiting Caused by Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • December 24, 1993; (Issue 912)
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table...
Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.
Ondansentron To Prevent Vomiting After Cancer Chemotherapy
The Medical Letter on Drugs and Therapeutics • June 28, 1991; (Issue 847)
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An...
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many other countries.